2cureX AB (OSTO:2CUREX) Change In Receivables : kr0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB Change In Receivables?

2cureX AB's change in receivables for the quarter that ended in Sep. 2023 was kr0.00 Mil. It means 2cureX AB's Accounts Receivable stayed the same from Jun. 2023 to Sep. 2023 .

2cureX AB's change in receivables for the fiscal year that ended in Dec. 2022 was kr0.31 Mil. It means 2cureX AB's Accounts Receivable declined by kr0.31 Mil from Dec. 2021 to Dec. 2022 .

2cureX AB's Accounts Receivable for the quarter that ended in Sep. 2023 was kr2.59 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. 2cureX AB's Days Sales Outstanding for the three months ended in Sep. 2023 was 2,717.57.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. 2cureX AB's liquidation value for the three months ended in Sep. 2023 was kr16.31 Mil.

2cureX AB Change In Receivables Historical Data

The historical data trend for 2cureX AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB Change In Receivables Chart

2cureX AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

0.79

-0.35

-0.68

0.33

0.31

2cureX AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

2cureX AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

2cureX AB (OSTO:2CUREX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

2cureX AB's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.591	/	0.087	*	91
=	2,717.57

2. In Ben Graham's calculation of liquidation value, 2cureX AB's accounts receivable are only considered to be worth 75% of book value:

2cureX AB's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	18.104	-	3.74	+	0.75 * 2.591	+	0.5 * 0
=	16.31

2cureX AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of 2cureX AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

2cureX AB (OSTO:2CUREX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

2QE:Germany

Address

Fruebjergvej 3, Copenhagen, DNK, DK-2100

Website

https://www.2curex.com

2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines